PET/CT restaging alters breast cancer management
FDG-PET/CT's power for staging and restaging breast cancer is attracting attention. It could also detect recurrence in more than two-thirds of these patients and change the management plan in up to a third, according to German investigators.
FDG-PET/CT's power for staging and restaging breast cancer is attracting attention. It could also detect recurrence in more than two-thirds of these patients and change the management plan in up to a third, according to German investigators.
Dr. Michael Souvatzoglou and colleagues in the nuclear medicine department at the Technical University of Munich prospectively enrolled 118 patients with suspicion of breast cancer recurrence based on elevated tumor markers, clinical signs, and abnormal standard imaging studies. PET/CT identified local and metastatic disease in 79 cases.
Follow-up data on 87 patients showed that a change in therapeutic management was made for 29 patients (33%) based on PET/CT findings. Changes included initiation of chemotherapy in 14, initiation of radiotherapy in 12, and initiation of chemoradiotherapy in three. Souvatzoglou presented his group's results at the 2008 SNM.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
